Congress Discusses Remaining FY2024 Spending Bill With Provisions On Cannabis Sales And Psychedelic Clinical Trials
On March 20, Congressional leaders at both the House and Senate Appropriations Committees released new spending legislation that would continue blocking Washington D.C.’s legal marijuana sales and fund psychedelic clinical studies.
The new Financial Services and General Government legislation follows an agreement on the remaining FY 2024 spending (second and final round,) and legislators aim to pass it before a close deadline on the current continuing resolution, noted Marijuana Moment.
D.C.’s current rider, in effect since 2014, bans the use of local tax dollars for implementing a legal cannabis sales system. The new legislation would leave that ruling intact as does President Biden’s FY 2025 proposal despite D.C. voters having approved cannabis legalization at the ballot a decade ago.
Want to delve into the latest updates on cannabis regulations? Then join us at the upcoming Benzinga Cannabis Capital Conference in Florida at …